Loading…

COVID-19 : guidelines for pharmacists in South Africa

Since the outbreak of COVID-19, and its declaration as a pandemic by the World Health Organization (WHO), the reliance on pharmacists as one of the first points of contact within the healthcare system has been highlighted. This evidence-based review is aimed at providing guidance for pharmacists in...

Full description

Saved in:
Bibliographic Details
Published in:South Africa Pharmaceutical Journal 2020-09, Vol.87 (3), p.13-21
Main Authors: Schellack, N. Schellack, Coetzee, M. Coetzee, Schellack, G. Schellack, Gijzelaar, M. Gijzelaar, Hassim, Z. Hassim, Milne, M. Milne, Bronkhorst, E. Bronkhorst, Padayachee, N. Padayachee, Singh, N. Singh, Kolman, S. Kolman, Gray, A.L. Gray
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 21
container_issue 3
container_start_page 13
container_title South Africa Pharmaceutical Journal
container_volume 87
creator Schellack, N. Schellack
Coetzee, M. Coetzee
Schellack, G. Schellack
Gijzelaar, M. Gijzelaar
Hassim, Z. Hassim
Milne, M. Milne
Bronkhorst, E. Bronkhorst
Padayachee, N. Padayachee
Singh, N. Singh
Kolman, S. Kolman
Gray, A.L. Gray
description Since the outbreak of COVID-19, and its declaration as a pandemic by the World Health Organization (WHO), the reliance on pharmacists as one of the first points of contact within the healthcare system has been highlighted. This evidence-based review is aimed at providing guidance for pharmacists in community, hospital and other settings in South Africa, on the management of patients with suspected or confirmed coronavirus disease 2019, or COVID-19. The situation is rapidly evolving, and new evidence continues to emerge on a daily basis. This guidance document takes into account and includes newly available evidence and recommendations, particularly around the following aspects relating to COVID-19:• Epidemiology• The virus, its modes of transmission and incubation period• Symptom identification, including the diefrentiation between influenza, allergic rhinitis, sinusitis and COVID-19• Social media myths and misinformation• Treatment guidelines and medicines that may need to be kept in stock• Treatment and prevention options, including an update on vaccine development• The case for and against the use of NSAIDs, ACE-inhibitors and angiotensin receptor blockers (ARBs) in patients with COVID-19• Interventions and patient counselling by the pharmacist. It is critical, though, that pharmacists access the most recent and authoritative information to guide their practice. Key websites that can be relied upon are:• World Health Organization (WHO): https://www.who.int/emergencies/diseases/novel- coronavirus-2019• National Institute for Communicable Diseases (NICD): https://www.nicd.ac.za/diseases- a-z-index/covid-19/• National Department of Health (NDoH): http://www.health.gov.za/index.php/ outbreaks/145-corona-virus-outbreak/465-corona-virusoutbreak; https://sacoronavirus. co.za/ S Afr Pharm J
doi_str_mv 10.10520/ejc-mp_sapj-v87-n3-a4
format article
fullrecord <record><control><sourceid>proquest_sabin</sourceid><recordid>TN_cdi_proquest_journals_2544477226</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sabinet_id>https://hdl.handle.net/10520/ejc-mp_sapj-v87-n3-a4</sabinet_id><sourcerecordid>2544477226</sourcerecordid><originalsourceid>FETCH-LOGICAL-p176t-bcd0159aee2e70e47f4d114d939ee9b03a2b208cfe264dcc9e08fc0166511feb3</originalsourceid><addsrcrecordid>eNot0N9LwzAQB_AgCo65f0ECPkeTNGla38Z0czDYgz9eQ35cbEfX1ib177due7qD-3J3fBC6Z_SRUcnpExwcOfY6mv5AfgtF2owYcYVmnHNKGGXq-tQzIgslb9EixtpSWkiqmCxmSK72X9sXwkr8jL_H2kNTtxBx6AbcV2Y4GlfHFHHd4vduTBVehqF25g7dBNNEWFzqHH2uXz9Wb2S332xXyx3pmcoTsc5TJksDwEFRECoIz5jwZVYClJZmhltOCxeA58I7VwItgqMszyVjAWw2Rw_nvf3Q_YwQkz5049BOJzWXQgilOM-n1PqcisZO36cJA_rR6iqlPurKN7oyrW9A_89OanpS0xc1PanpNtNGZH_QY2Sk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2544477226</pqid></control><display><type>article</type><title>COVID-19 : guidelines for pharmacists in South Africa</title><source>Publicly Available Content (ProQuest)</source><source>Coronavirus Research Database</source><creator>Schellack, N. Schellack ; Coetzee, M. Coetzee ; Schellack, G. Schellack ; Gijzelaar, M. Gijzelaar ; Hassim, Z. Hassim ; Milne, M. Milne ; Bronkhorst, E. Bronkhorst ; Padayachee, N. Padayachee ; Singh, N. Singh ; Kolman, S. Kolman ; Gray, A.L. Gray</creator><creatorcontrib>Schellack, N. Schellack ; Coetzee, M. Coetzee ; Schellack, G. Schellack ; Gijzelaar, M. Gijzelaar ; Hassim, Z. Hassim ; Milne, M. Milne ; Bronkhorst, E. Bronkhorst ; Padayachee, N. Padayachee ; Singh, N. Singh ; Kolman, S. Kolman ; Gray, A.L. Gray</creatorcontrib><description>Since the outbreak of COVID-19, and its declaration as a pandemic by the World Health Organization (WHO), the reliance on pharmacists as one of the first points of contact within the healthcare system has been highlighted. This evidence-based review is aimed at providing guidance for pharmacists in community, hospital and other settings in South Africa, on the management of patients with suspected or confirmed coronavirus disease 2019, or COVID-19. The situation is rapidly evolving, and new evidence continues to emerge on a daily basis. This guidance document takes into account and includes newly available evidence and recommendations, particularly around the following aspects relating to COVID-19:• Epidemiology• The virus, its modes of transmission and incubation period• Symptom identification, including the diefrentiation between influenza, allergic rhinitis, sinusitis and COVID-19• Social media myths and misinformation• Treatment guidelines and medicines that may need to be kept in stock• Treatment and prevention options, including an update on vaccine development• The case for and against the use of NSAIDs, ACE-inhibitors and angiotensin receptor blockers (ARBs) in patients with COVID-19• Interventions and patient counselling by the pharmacist. It is critical, though, that pharmacists access the most recent and authoritative information to guide their practice. Key websites that can be relied upon are:• World Health Organization (WHO): https://www.who.int/emergencies/diseases/novel- coronavirus-2019• National Institute for Communicable Diseases (NICD): https://www.nicd.ac.za/diseases- a-z-index/covid-19/• National Department of Health (NDoH): http://www.health.gov.za/index.php/ outbreaks/145-corona-virus-outbreak/465-corona-virusoutbreak; https://sacoronavirus. co.za/ S Afr Pharm J</description><identifier>ISSN: 2221-5875</identifier><identifier>EISSN: 2220-1017</identifier><identifier>DOI: 10.10520/ejc-mp_sapj-v87-n3-a4</identifier><language>eng</language><publisher>Lynnwood Ridge: Medpharm Publications</publisher><subject>Chloroquine ; Corona virus disease ; Coronaviruses ; COVID-19 ; Disease transmission ; Epidemics ; Hydroxychloroquine ; MERS-CoV ; Novel coronavirus (2019-nCoV) ; Pandemic ; Pharmacists ; SARS-CoV ; SARS-CoV-2 ; Spill-over</subject><ispartof>South Africa Pharmaceutical Journal, 2020-09, Vol.87 (3), p.13-21</ispartof><rights>2020. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at http://www.sapj.co.za/index.php/SAPJ/about/submissions</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2544477226?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,38516,43895,44590</link.rule.ids></links><search><creatorcontrib>Schellack, N. Schellack</creatorcontrib><creatorcontrib>Coetzee, M. Coetzee</creatorcontrib><creatorcontrib>Schellack, G. Schellack</creatorcontrib><creatorcontrib>Gijzelaar, M. Gijzelaar</creatorcontrib><creatorcontrib>Hassim, Z. Hassim</creatorcontrib><creatorcontrib>Milne, M. Milne</creatorcontrib><creatorcontrib>Bronkhorst, E. Bronkhorst</creatorcontrib><creatorcontrib>Padayachee, N. Padayachee</creatorcontrib><creatorcontrib>Singh, N. Singh</creatorcontrib><creatorcontrib>Kolman, S. Kolman</creatorcontrib><creatorcontrib>Gray, A.L. Gray</creatorcontrib><title>COVID-19 : guidelines for pharmacists in South Africa</title><title>South Africa Pharmaceutical Journal</title><description>Since the outbreak of COVID-19, and its declaration as a pandemic by the World Health Organization (WHO), the reliance on pharmacists as one of the first points of contact within the healthcare system has been highlighted. This evidence-based review is aimed at providing guidance for pharmacists in community, hospital and other settings in South Africa, on the management of patients with suspected or confirmed coronavirus disease 2019, or COVID-19. The situation is rapidly evolving, and new evidence continues to emerge on a daily basis. This guidance document takes into account and includes newly available evidence and recommendations, particularly around the following aspects relating to COVID-19:• Epidemiology• The virus, its modes of transmission and incubation period• Symptom identification, including the diefrentiation between influenza, allergic rhinitis, sinusitis and COVID-19• Social media myths and misinformation• Treatment guidelines and medicines that may need to be kept in stock• Treatment and prevention options, including an update on vaccine development• The case for and against the use of NSAIDs, ACE-inhibitors and angiotensin receptor blockers (ARBs) in patients with COVID-19• Interventions and patient counselling by the pharmacist. It is critical, though, that pharmacists access the most recent and authoritative information to guide their practice. Key websites that can be relied upon are:• World Health Organization (WHO): https://www.who.int/emergencies/diseases/novel- coronavirus-2019• National Institute for Communicable Diseases (NICD): https://www.nicd.ac.za/diseases- a-z-index/covid-19/• National Department of Health (NDoH): http://www.health.gov.za/index.php/ outbreaks/145-corona-virus-outbreak/465-corona-virusoutbreak; https://sacoronavirus. co.za/ S Afr Pharm J</description><subject>Chloroquine</subject><subject>Corona virus disease</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Disease transmission</subject><subject>Epidemics</subject><subject>Hydroxychloroquine</subject><subject>MERS-CoV</subject><subject>Novel coronavirus (2019-nCoV)</subject><subject>Pandemic</subject><subject>Pharmacists</subject><subject>SARS-CoV</subject><subject>SARS-CoV-2</subject><subject>Spill-over</subject><issn>2221-5875</issn><issn>2220-1017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><recordid>eNot0N9LwzAQB_AgCo65f0ECPkeTNGla38Z0czDYgz9eQ35cbEfX1ib177due7qD-3J3fBC6Z_SRUcnpExwcOfY6mv5AfgtF2owYcYVmnHNKGGXq-tQzIgslb9EixtpSWkiqmCxmSK72X9sXwkr8jL_H2kNTtxBx6AbcV2Y4GlfHFHHd4vduTBVehqF25g7dBNNEWFzqHH2uXz9Wb2S332xXyx3pmcoTsc5TJksDwEFRECoIz5jwZVYClJZmhltOCxeA58I7VwItgqMszyVjAWw2Rw_nvf3Q_YwQkz5049BOJzWXQgilOM-n1PqcisZO36cJA_rR6iqlPurKN7oyrW9A_89OanpS0xc1PanpNtNGZH_QY2Sk</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Schellack, N. Schellack</creator><creator>Coetzee, M. Coetzee</creator><creator>Schellack, G. Schellack</creator><creator>Gijzelaar, M. Gijzelaar</creator><creator>Hassim, Z. Hassim</creator><creator>Milne, M. Milne</creator><creator>Bronkhorst, E. Bronkhorst</creator><creator>Padayachee, N. Padayachee</creator><creator>Singh, N. Singh</creator><creator>Kolman, S. Kolman</creator><creator>Gray, A.L. Gray</creator><general>Medpharm Publications</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20200901</creationdate><title>COVID-19 : guidelines for pharmacists in South Africa</title><author>Schellack, N. Schellack ; Coetzee, M. Coetzee ; Schellack, G. Schellack ; Gijzelaar, M. Gijzelaar ; Hassim, Z. Hassim ; Milne, M. Milne ; Bronkhorst, E. Bronkhorst ; Padayachee, N. Padayachee ; Singh, N. Singh ; Kolman, S. Kolman ; Gray, A.L. Gray</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p176t-bcd0159aee2e70e47f4d114d939ee9b03a2b208cfe264dcc9e08fc0166511feb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Chloroquine</topic><topic>Corona virus disease</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Disease transmission</topic><topic>Epidemics</topic><topic>Hydroxychloroquine</topic><topic>MERS-CoV</topic><topic>Novel coronavirus (2019-nCoV)</topic><topic>Pandemic</topic><topic>Pharmacists</topic><topic>SARS-CoV</topic><topic>SARS-CoV-2</topic><topic>Spill-over</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schellack, N. Schellack</creatorcontrib><creatorcontrib>Coetzee, M. Coetzee</creatorcontrib><creatorcontrib>Schellack, G. Schellack</creatorcontrib><creatorcontrib>Gijzelaar, M. Gijzelaar</creatorcontrib><creatorcontrib>Hassim, Z. Hassim</creatorcontrib><creatorcontrib>Milne, M. Milne</creatorcontrib><creatorcontrib>Bronkhorst, E. Bronkhorst</creatorcontrib><creatorcontrib>Padayachee, N. Padayachee</creatorcontrib><creatorcontrib>Singh, N. Singh</creatorcontrib><creatorcontrib>Kolman, S. Kolman</creatorcontrib><creatorcontrib>Gray, A.L. Gray</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>South Africa Pharmaceutical Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schellack, N. Schellack</au><au>Coetzee, M. Coetzee</au><au>Schellack, G. Schellack</au><au>Gijzelaar, M. Gijzelaar</au><au>Hassim, Z. Hassim</au><au>Milne, M. Milne</au><au>Bronkhorst, E. Bronkhorst</au><au>Padayachee, N. Padayachee</au><au>Singh, N. Singh</au><au>Kolman, S. Kolman</au><au>Gray, A.L. Gray</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID-19 : guidelines for pharmacists in South Africa</atitle><jtitle>South Africa Pharmaceutical Journal</jtitle><date>2020-09-01</date><risdate>2020</risdate><volume>87</volume><issue>3</issue><spage>13</spage><epage>21</epage><pages>13-21</pages><issn>2221-5875</issn><eissn>2220-1017</eissn><abstract>Since the outbreak of COVID-19, and its declaration as a pandemic by the World Health Organization (WHO), the reliance on pharmacists as one of the first points of contact within the healthcare system has been highlighted. This evidence-based review is aimed at providing guidance for pharmacists in community, hospital and other settings in South Africa, on the management of patients with suspected or confirmed coronavirus disease 2019, or COVID-19. The situation is rapidly evolving, and new evidence continues to emerge on a daily basis. This guidance document takes into account and includes newly available evidence and recommendations, particularly around the following aspects relating to COVID-19:• Epidemiology• The virus, its modes of transmission and incubation period• Symptom identification, including the diefrentiation between influenza, allergic rhinitis, sinusitis and COVID-19• Social media myths and misinformation• Treatment guidelines and medicines that may need to be kept in stock• Treatment and prevention options, including an update on vaccine development• The case for and against the use of NSAIDs, ACE-inhibitors and angiotensin receptor blockers (ARBs) in patients with COVID-19• Interventions and patient counselling by the pharmacist. It is critical, though, that pharmacists access the most recent and authoritative information to guide their practice. Key websites that can be relied upon are:• World Health Organization (WHO): https://www.who.int/emergencies/diseases/novel- coronavirus-2019• National Institute for Communicable Diseases (NICD): https://www.nicd.ac.za/diseases- a-z-index/covid-19/• National Department of Health (NDoH): http://www.health.gov.za/index.php/ outbreaks/145-corona-virus-outbreak/465-corona-virusoutbreak; https://sacoronavirus. co.za/ S Afr Pharm J</abstract><cop>Lynnwood Ridge</cop><pub>Medpharm Publications</pub><doi>10.10520/ejc-mp_sapj-v87-n3-a4</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2221-5875
ispartof South Africa Pharmaceutical Journal, 2020-09, Vol.87 (3), p.13-21
issn 2221-5875
2220-1017
language eng
recordid cdi_proquest_journals_2544477226
source Publicly Available Content (ProQuest); Coronavirus Research Database
subjects Chloroquine
Corona virus disease
Coronaviruses
COVID-19
Disease transmission
Epidemics
Hydroxychloroquine
MERS-CoV
Novel coronavirus (2019-nCoV)
Pandemic
Pharmacists
SARS-CoV
SARS-CoV-2
Spill-over
title COVID-19 : guidelines for pharmacists in South Africa
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T19%3A42%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_sabin&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID-19%20:%20guidelines%20for%20pharmacists%20in%20South%20Africa&rft.jtitle=South%20Africa%20Pharmaceutical%20Journal&rft.au=Schellack,%20N.%20Schellack&rft.date=2020-09-01&rft.volume=87&rft.issue=3&rft.spage=13&rft.epage=21&rft.pages=13-21&rft.issn=2221-5875&rft.eissn=2220-1017&rft_id=info:doi/10.10520/ejc-mp_sapj-v87-n3-a4&rft_dat=%3Cproquest_sabin%3E2544477226%3C/proquest_sabin%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p176t-bcd0159aee2e70e47f4d114d939ee9b03a2b208cfe264dcc9e08fc0166511feb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2544477226&rft_id=info:pmid/&rft_sabinet_id=https://hdl.handle.net/10520/ejc-mp_sapj-v87-n3-a4&rfr_iscdi=true